Q-omics provides the consensus-scored ANKRD40CL profile across patient tissues and cancer cell-line models. ANKRD40CL expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, ANKRD40CL is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, ANKRD40CL RNA expression shows 9,105 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight BLCA, KIRC, and ESCA as cancer lineages where ANKRD40CL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD40CL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD40CL survival associations across molecular data types. ANKRD40CL RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD40CL RNA expression–survival associations across cancer types. High ANKRD40CL expression shows unfavorable associations in UCEC, ESCA, OV, PRAD and STAD, but favorable associations in BLCA. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for ANKRD40CL RNA expression.
This table summarizes ANKRD40CL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ANKRD40CL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD40CL shows lower tumor expression in COAD, KICH and READ and higher tumor expression in KIRC, LIHC and BRCA. The KIRC box plot shows higher ANKRD40CL RNA expression in tumor versus normal tissue (log2 FC = +0.082, t-test p < 0.001).
This table shows molecular features associated with ANKRD40CL in patient tissues and cancer cell lines. In patient samples, ANKRD40CL shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKRD40CL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE.
